Science
Mechanism of Action
This synthetic peptide specifically targets the CD90 receptor found on skin keratinocytes and fibroblasts. By binding, it orchestrates a cascade of regenerative processes including enhanced skin cell renewal, accelerated wound healing, improved microvessel formation, optimized oxygen and nutrient delivery to tissues, and the stimulation of crucial growth factors.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Manufacturer's clinical trials indicate significant beneficial effects against signs of skin aging, alleviating acne symptoms, and mitigating UV-induced irritation.
- 02 It is a key active component within Augustinus Bader's patented Trigger Factor Complex (TFC), widely used in their skincare formulations.
Transparency
Dusting Analysis
The Formula
Formulation
Synergies
- Effectively delivered via a lipid structure with ceramides, accompanied by amino acids that act as triggering agents, as observed in Augustinus Bader's TFC.
Safety
Safety Profile
Oligopeptide-177 Trifluoroacetate has not undergone specific review by the Cosmetic Ingredient Review (CIR) or the SCCS. The 'trifluoroacetate' component is a fluorinated compound classified as a potential PFA (Per- and Polyfluoroalkyl Substance), known for persistence and potential health concerns. A related ingredient containing trifluoroacetate (Tetradecyl Aminobutyroylvalylaminobutyric Urea Trifluoroacetate) has received an alarming EWG safety rating of 10 (unsafe), highlighting a general concern with this counterion, though this specific rating is not directly assigned to Oligopeptide-177 Trifluoroacetate.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While Oligopeptide-177 Trifluoroacetate demonstrates potent regenerative and protective skin benefits in manufacturer trials, its classification with a trifluoroacetate counterion raises significant concerns regarding potential PFA presence and overall safety, pending independent review.
Related
Similar Ingredients
Finding similar ingredients…